Unpacking LEVEL UP Period 2 Data With Dr. Christopher Bunick: Patients Who Switched From Dupilumab to Upadacitinib Hit Higher AD Treatment Targets
Atopic dermatitis (AD) patients who switched to upadacitinib (Rinvoq, AbbVie) from dupilumab (Dupixent, Regeneron, and Sanofi) hit higher treatment targets, according to results from Period 2 of the LEVEL UP study presented at the 2024 Fall Clinical Dermatology Conference in Las Vegas, NV. “At a big picture level, Period 2 data tells us what happens […]